Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tandem HDCT/ASCR in High-risk Neuroblastoma
NCT00793845Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Aug 2008
- Primary completion
- Jan 2015
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, etoposide, carboplatin, thiotepa, melphalan in neuroblastoma, sponsored by Samsung Medical Center. Started Aug 2008; status: completed.
02
Drugs
cyclophosphamideetoposidecarboplatinthiotepamelphalan
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT00793845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00793845.